XMAD
ATRY
Market cap226mUSD
Oct 20, Last price
2.66EUR
1D
0.38%
1Q
6.40%
Jan 2017
79.73%
IPO
58.33%
Name
Atrys Health SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
Related entities
Subsidiaries (4)
ATRYS HEALTH INTERNACIONAL SA
EDIAGNOSTIC CLINICA VIRTUAL DE ESPECIALIDADES MEDICAS S.L.(SOCIEDAD UNIPERSONAL)
ASPY PREVENCION S.L. (SOCIEDAD UNIPERSONAL)
Key people
Santiago De Torres Sanahuja
Chairman of the Board, Other External Director · since 2025
Jose Maria Huch Ginesta
Chief Financial Officer · since 2015
Luis De Gregorio Cudos
Director - Finance · since 2021
Juan Mella
Country Manager, Chile, Director - Business Development, Latin America · since 2024
Pedro Salord Betrand
Chief Human Resource Officer · since 2021
Luis Duran Vizan
Global Chief Technology Officer · since 2023
Encarna Vega
Chief Administrative Officer · since 2007
Alfonso Alba
Partner, Vice President - Genetics · since 2020
Benjamin Guix
Vice President - Oncology, Medical Director of IMOR · since 2019
Garbriela Camunas Caruana
General Counsel · since 2020
Ana Alarcon Perez
Managing Director - Prevention
Maria Antonia Isach Gabaldon
Managing Director - Oncology · since 2022
Nicolas Achkar Tuglaman
Director - Clinical Telemedicine · since 2018
Graca Andrade Pires
Country Manager, Portugal · since 2021
Diana Barriga Rodriguez
Director - Communication and Culture
Ana Belen Galvan
Director - Technical · since 2011
Severino Gonzalez
Chief Technology Officer - Genetics
Victor Gonzalez-Rumayor
Director - Research and Development · since 2015
Gabriela Guzman Martinez
Medical Director - Cardiology · since 2015
Ignacio Hernandez
Director - Big Data
Headquarters & legal address
Calle Velázquez 157 4 A
Madrid 28002
ES
Madrid 28002
ES
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||